Fig. 2From: The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancersSchematic of resistant mechanisms involving DDR in response to immune checkpoint therapy by influencing Teff. DNA damage response (DDR); effector T-cells (Teff); tumor mutation burden (TMB); major histocompatibility complex (MHC)Back to article page